NCT06507436View on ClinicalTrials.gov

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

September 30, 2025

Conditions
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Interventions
DRUG

Herombopag tablets

Herombopag tablets; dose 1 or dose 2, for 5 days

DRUG

Herombopag placebo tablets

Herombopag placebo tablets; dose 1 or dose 2, for 5 days

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, affiliated with Fudan University, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY